GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Heska Corp (NAS:HSKA) » Definitions » EBIT

Heska (HSKA) EBIT : $-16.4 Mil (TTM As of Mar. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Heska EBIT?

Heska's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2023 was $-9.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2023 was $-16.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Heska's annualized ROC % for the quarter that ended in Mar. 2023 was -9.65%. Heska's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -31.20%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Heska's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was -1.27%.


Heska EBIT Historical Data

The historical data trend for Heska's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heska EBIT Chart

Heska Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.12 0.51 -7.42 0.76 -17.64

Heska Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.89 -5.54 0.26 -1.92 -9.21

Competitive Comparison of Heska's EBIT

For the Medical Devices subindustry, Heska's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heska's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Heska's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Heska's EV-to-EBIT falls into.



Heska EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heska  (NAS:HSKA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Heska's annualized ROC % for the quarter that ended in Mar. 2023 is calculated as:

ROC % (Q: Mar. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Mar. 2023 ))/ count )
=-41.692 * ( 1 - 3.69% )/( (397.646 + 434.394)/ 2 )
=-40.1535652/416.02
=-9.65 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=585.816 - 31.552 - ( 156.618 - max(0, 39.577 - 265.034+156.618))
=397.646

Invested Capital(Q: Mar. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=592.715 - 33.112 - ( 125.209 - max(0, 42.298 - 238.621+125.209))
=434.394

Note: The Operating Income data used here is four times the quarterly (Mar. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Heska's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2022  Q: Mar. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.848/( ( (39.068 + max(64.35, 0)) + (68.131 + max(64.678, 0)) )/ 2 )
=-36.848/( ( 103.418 + 132.809 )/ 2 )
=-36.848/118.1135
=-31.20 %

where Working Capital is:

Working Capital(Q: Dec. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(29.493 + 60.05 + 11.44) - (31.552 + 5.081 + -7.105427357601E-15)
=64.35

Working Capital(Q: Mar. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26.054 + 64.183 + 12.69) - (33.112 + 5.137 + 0)
=64.678

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Heska's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2023 )
=-16.416/1293.764
=-1.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Heska EBIT Related Terms

Thank you for viewing the detailed overview of Heska's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Heska (HSKA) Business Description

Traded in Other Exchanges
N/A
Address
3760 Rocky Mountain Avenue, Loveland, CO, USA, 80538
Heska Corp is engaged in developing, manufacturing, marketing, selling, and supporting veterinary products. The company's products include Point of Care diagnostic laboratory instruments and consumables; Point of Care digital imaging diagnostic products; reference laboratory testing; digital cytology services; vaccines; local and cloud-based data services; allergy testing and immunotherapy; single-use offerings such as in-clinic diagnostic tests and heartworm preventive products; and practice information management software and related software. It operates through two segments North America and International. The Company's core strategic focus on Point of Care laboratory and imaging products is included in both segments.
Executives
Joachim A. Hasenmaier director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Robert L Antin director
Mark F Furlong director 770 M WATER ST, MILWAUKEE WI 53202
Stephen L Davis director 2901 BUTTERFIELD ROAD, OAK BROOK IL 60523
Providenti Anthony C. Jr. officer: EVP, Corporate Development 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Kevin S. Wilson officer: President and COO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Eleanor F. Baker officer: EVP, Managing Dir. & COO, scil 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Christopher D. Sveen officer: CAO & General Counsel 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Nancy Wisnewski officer: EVP, Prod. Dev. & Cust. Supp 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Sharon L. Riley director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Catherine Grassman officer: EVP, CFO 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason D Aroesty officer: EVP, International Diagnostics 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Bonnie J. Trowbridge director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Scott Humphrey director 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO 80538
Jason A Napolitano officer: Exec. VP, CFO & Secretary 1613 PROSPECT PARKWAY, FORT COLLINS CO 80525